This project seeks to develop a quantitative imaging biomarker for evaluating and monitoring treatment response in ovarian cancer metastases and assess its potential in monitoring treatment response. This will involve standardising DW-MRI for the abdomen and pelvis across multiple centres and platforms, assessing reproducibility of the measurement in patients planned for neoadjuvant chemotherapy and assessing its utility as an early response biomarker in patients with platinum-sensitive relapse due to receive therapy with carboplatin. Scanning measurements will be correlated with histopathological markers in tumour samples in order to link the biomarker with response mechanisms.
Study Type
OBSERVATIONAL
Enrollment
134
Addenbrookes Hospital, Cambridge University Hospitals NHS Foundation Trust
Cambridge, Cambridgeshire, United Kingdom
Queen Elizabeth Hospital
Newcastle, Gateshead, United Kingdom
Mount Vernon Cancer Centre
Northwood, Middlesex, United Kingdom
The Institute of Cancer Research and Royal Marsden NHS Foundation Trust
Sutton, Surrey, United Kingdom
Singleton Hospital
Swansea, Wales, United Kingdom
Imperial College Healthcare NHS Trust
London, United Kingdom
Development of a Quantitative Imaging Biomarker for Evaluating Ovarian Cancer Metastases and Assessment of its Potential in Monitoring Treatment Response.
Diffusion-weighted magnetic resonance imaging (DW-MRI) for visualising peritoneal metastases will be developed.Reproducibility will be assessed in a multi-centre setting across multiple vendor platforms and field strengths by comparing 2 baseline scans per person and plotting absolute difference in ADC against mean of the 2 measurements.Biological validation will be achieved by correlating scan data (ADC change) following chemotherapy with histology of the tumour(amount of cell death) at surgery.
Time frame: 4.0 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.